Shares of Adaptive Biotechnologies Corp (NASDAQ: ADPT) surged more than 12% in pre-market trading on Thursday, following a positive analyst report from TD Cowen. The biotechnology company, which specializes in immune medicine, received a reiterated "Buy" rating from analyst Daniel Brennan.
In his report, Brennan highlighted Adaptive Biotechnologies' potential for growth and innovation in the field of immune-driven medicine. The analyst's optimism likely contributed to the significant pre-market rally in the company's stock price.
While the specific details of Brennan's report were not disclosed, his reiteration of a "Buy" rating suggests confidence in the company's prospects and future performance. Analyst upgrades and positive coverage can often drive short-term stock movements, as investors react to the revised expectations and valuations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。